Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition

被引:13
作者
Narita, M
Murata, T
Shimizu, K
Sugiyama, T
Nakagawa, T
Manganiello, VC
Tagawa, T
机构
[1] Mie Univ, Fac Med, Dept Oral & Maxillofacial Surg, Tsu, Mie 5148507, Japan
[2] NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD USA
关键词
osteoblastic osteosarcoma; phosphodiesterase;
D O I
10.1097/00001813-200306000-00009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Reverse transcription-polymerise chain reaction (RT-PCR) analysis revealed that HOSM-1 cells, an osteosarcoma cell line established from human mandible, expressed mRNA for osteoblastic markers, such as alkaline phosphatase, osteonectin, osteocalcin and parathyroid hormone receptor, thus exhibiting an osteoblastic phenotype. We have investigated a possible role of cyclic nucleotide phosphodiesterases (PDEs) in osteosarcoma cells. RT-PCR analysis revealed that HOSM-1 cells expressed mRNA for PDE4A, 413 and 4C. In addition, rolipram, a specific inhibitor of PDE4, inhibited HOSM-1 cell proliferation. The finding that PDE4 is involved in proliferation of osteosarcoma cells suggests the possibility that PDE4 may be a new target for antitumor therapy. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:377 / 381
页数:5
相关论文
共 50 条
  • [1] Expression profiles of phosphodiesterase 4D splicing variants in osteoblastic cells
    Chizumi Nomura-Furuwatari
    Shigeyuki Wakitani
    Yusuke Hashimoto
    Yuuki Imai
    Yoichi Ohta
    Keisuke Nakagawa
    Yoshihiro Nakao
    Kazushi Takayama
    Tomoya Manaka
    Kunio Takaoka
    Journal of Bone and Mineral Metabolism, 2008, 26 : 152 - 158
  • [2] Expression profiles of phosphodiesterase 4D splicing variants in osteoblastic cells
    Nomura-Furuwatari, Chizumi
    Wakitani, Shigeyuki
    Hashimoto, Yusuke
    Imai, Yuuki
    Ohta, Yoichi
    Nakagawa, Keisuke
    Nakao, Yoshihiro
    Takayama, Kazushi
    Manaka, Tomoya
    Takaoka, Kunio
    JOURNAL OF BONE AND MINERAL METABOLISM, 2008, 26 (02) : 152 - 158
  • [3] Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis
    Keith, Rebecca
    Nambiar, Anoop M.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2025, 19
  • [4] Clinical Implication of Phosphodiesterase-4-Inhibition
    Schick, Martin Alexander
    Schlegel, Nicolas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [5] ROLIPRAM INHIBITION OF PHOSPHODIESTERASE-4 ACTIVATION
    DISANTO, ME
    HEASLIP, RJ
    EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1995, 290 (02): : 169 - 172
  • [6] Preferential inhibition of human phosphodiesterase 4 by ibudilast
    Huang, Z
    Liu, S
    Zhang, L
    Salem, M
    Greig, GM
    Chan, CC
    Natsumeda, Y
    Noguchi, K
    LIFE SCIENCES, 2006, 78 (23) : 2663 - 2668
  • [7] Role of Phosphodiesterase2A in Proliferation and Migration of Human Osteosarcoma Cells
    Murata, Taku
    Shimizu, Kasumi
    Kurohara, Kazuto
    Tomeoku, Akira
    Koizumi, Gaku
    Arai, Naoya
    ANTICANCER RESEARCH, 2019, 39 (11) : 6057 - 6062
  • [8] To Target or Not to Target Schistosoma mansoni Cyclic Nucleotide Phosphodiesterase 4A?
    Zheng, Yang
    Schroeder, Susanne
    Kanev, Georgi K.
    Botros, Sanaa S.
    William, Samia
    Sabra, Abdel-Nasser A.
    Maes, Louis
    Caljon, Guy
    Gil, Carmen
    Martinez, Ana
    Salado, Irene G.
    Augustyns, Koen
    Edink, Ewald
    Sijm, Maarten
    de Heuvel, Erik
    de Esch, Iwan J. P.
    van der Meer, Tiffany
    Siderius, Marco
    Sterk, Geert Jan
    Brown, David
    Leurs, Rob
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [9] Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells
    Ahlström, M
    Pekkinen, M
    Huttunen, M
    Lamberg-Allardt, C
    BIOCHEMICAL PHARMACOLOGY, 2005, 69 (02) : 267 - 275
  • [10] Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy
    Hinkle, RT
    Dolan, E
    Cody, DB
    Bauer, MB
    Isfort, RJ
    MUSCLE & NERVE, 2005, 32 (06) : 775 - 781